<DOC>
	<DOCNO>NCT00959127</DOCNO>
	<brief_summary>This Phase 1 study patient advance solid tumor receive investigational study drug ARRY-438162 ( MEK162 ) . This study 3 part . In first part , patient advance solid tumor receive increase dos study drug order achieve high dose study drug possible cause unacceptable side effect . Approximately 30 patient US enrol Part 1 . ( Active , recruit ) In second part study , patient advance metastatic biliary cancer receive best dose study drug determine first part study follow see side effect effectiveness study drug , , treat cancer . Approximately 25 patient US enrol Part 2 . ( Active , recruit ) In third part study , patient metastatic colorectal cancer ( CRC ) receive best dose study drug determine first part study follow see side effect effectiveness study drug , , treat cancer . Approximately 25 patient KRAS mutation ( Active , recruit ) 15 patient BRAF mutation ( Active , recruit ) US enrol Part 3 .</brief_summary>
	<brief_title>A Study ARRY-438162 ( MEK162 ) Patients With Advanced Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>Key Inclusion Criteria ( Part 3 ) : A histologically cytologically confirm diagnosis colorectal adenocarcinoma metastatic ( measurable disease ) . Documented KRAS BRAF tumor mutation . Previously treat unsuitable treatment 5Fluorouracil ( 5FU ) , oxaliplatin , irinotecan , available , bevacizumab . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 2 . Additional criterion exist . Key Exclusion Criteria ( Part 3 ) : Uncontrolled symptomatic brain metastasis ( patient brain metastasis steroid , steroid dose must stable least 30 day ) . History central serous retinopathy , retinopathy visible baseline would consider risk factor central serous retinopathy retinal vein occlusion . Concomitant malignancies previous malignancy less 2year disease free interval time enrollment ; patient adequately resect basal squamous cell carcinoma skin , carcinoma situ cervix , stage A low grade prostate cancer may enroll irrespective time diagnosis . Prior treatment MEK inhibitor . Treatment prior chemotherapy , anticancer immunotherapy , monoclonal antibody protein peptide therapeutic within 21 day first dose study drug . Treatment small molecule target agent anticancer hormonal therapy within 14 day first dose study drug . Treatment prior radiotherapy within 28 day initiate study drug ( radiation portal cover â‰¤ 10 % bone marrow reserve , patient may enrol irrespective end date radiotherapy ) . Major surgery within 4 week minor surgery within 7 day prior first dose study drug . Known positive serology human immunodeficiency virus ( HIV ) , hepatitis C , and/or active hepatitis B . Additional criterion exist .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Colorectal Adenocarcinoma</keyword>
	<keyword>Colon Cancer</keyword>
	<keyword>Rectal Cancer</keyword>
</DOC>